Information  X 
Enter a valid email address

Ashoka India Equity (AIE)

  Print      Mail a friend       Annual reports

Friday 08 November, 2019

Ashoka India Equity

Issue of Equity

RNS Number : 8582S
Ashoka India Equity Investment Tst
08 November 2019
 

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR TO INDIA, THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM) OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE OF THIS ANNOUNCEMENT WOULD BE UNLAWFUL.

 

8 November 2019

ASHOKA INDIA EQUITY INVESTMENT TRUST PLC

 

Issue of Ordinary Shares

 

Ashoka India Equity Trust plc (the "Company") announces that it has today issued 250,000 of its ordinary shares of one penny each ("Ordinary Shares") pursuant to its block listing facility. The Ordinary Shares will be issued at a price of 109.4 pence per Ordinary Share, a premium to the prevailing net asset value (cum income) per Ordinary Share.

 

Following the issue of Ordinary Shares, the Company's issued share capital will comprise 58,779,004 Ordinary Shares and this is the total number of Ordinary Shares with voting rights in the Company. This figure (58,779,004) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to, their interest in the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

The Company's LEI is 213800KX5ZS1NGAR2J89.

 

For further information please contact:

 

Peel Hunt LLP

Luke Simpson / Liz Yong / Tom Pocock (Corporate)

Mark Thompson (Sales)

Tel: 020 7418 8900

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOELLFFELELTIIA

a d v e r t i s e m e n t